GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Enterprise Value

Rosetta Genomics (Rosetta Genomics) Enterprise Value : $0.00 Mil (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rosetta Genomics's Enterprise Value is $0.00 Mil. Rosetta Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 was $-10.20 Mil. Therefore, Rosetta Genomics's EV-to-EBIT ratio for today is 0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Rosetta Genomics's Enterprise Value is $0.00 Mil. Rosetta Genomics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 was $-10.20 Mil. Therefore, Rosetta Genomics's EV-to-EBITDA ratio for today is 0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Rosetta Genomics's Enterprise Value is $0.00 Mil. Rosetta Genomics's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 was $5.09 Mil. Therefore, Rosetta Genomics's EV-to-Revenue ratio for today is 0.00.


Rosetta Genomics Enterprise Value Historical Data

The historical data trend for Rosetta Genomics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Enterprise Value Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.32 13.80 18.65 12.79 6.92

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.83 16.09 12.03 6.92 7.21

Competitive Comparison of Rosetta Genomics's Enterprise Value

For the Diagnostics & Research subindustry, Rosetta Genomics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Enterprise Value falls into.



Rosetta Genomics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Rosetta Genomics's Enterprise Value for the fiscal year that ended in Dec. 2016 is calculated as

Rosetta Genomics's Enterprise Value for the quarter that ended in Jun. 2017 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rosetta Genomics  (OTCPK:ROSGQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Rosetta Genomics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-10.201
=0.00

Rosetta Genomics's current Enterprise Value is $0.00 Mil.
Rosetta Genomics's EBIT for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.20 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Rosetta Genomics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.000/-10.201
=0.00

Rosetta Genomics's current Enterprise Value is $0.00 Mil.
Rosetta Genomics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.20 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Rosetta Genomics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/5.089
=0.00

Rosetta Genomics's current Enterprise Value is $0.00 Mil.
Rosetta Genomics's Revenue for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rosetta Genomics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458